Search clinical trials for: Docetaxel, Erlotinib

Total 3556 results

Hellenic Cooperative Oncology Group

Terminated

Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC) (DOPERLO)

Advanced Non-Small Cell Lung Cancer

Greece
Hospital Arnau de Vilanova

Unknown

Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen

Non-Small Cell Lung Cancer

Spain
Tianjin Medical University Cancer Institute and...

Recruiting

Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer

Non-small-cell Lung Cancer

China
Hunan Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Hunan Provincial People's...

Unknown

Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer

Non-small Cell Lung Cancer

China
University Hospital, Limoges
Hoffmann-La Roche

Completed

Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer (TARSEQ)

Non Small Cell Lung Cancer

France
Hoffmann-La Roche

Completed

A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN)

Non-Squamous Non-Small Cell Lung Cancer

Italy
Meir Medical Center

Completed

Study of Erlotinib With Docetaxel in Selected Non Small Cell Lung Cancer Patients in First Line Treatment

Non-Small Cell Lung Cancer

Israel
Mirati Therapeutics Inc.

Terminated

A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer

Advanced Malignancies, Non-small Cell Lung Cancer

United States
Paula Silverman, MD
National Cancer Institute (NCI)

Completed

Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer

Breast Cancer

United States
National Taiwan University Hospital

Unknown

Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca (Oncology)

Non-small Cell Lung Cancer(NSCLC)

Taiwan
Jonsson Comprehensive Cancer Center
Aventis Pharmaceuticals; Genentec

Completed

Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer

Prostate Cancer

United States
University of California, Davis
National Cancer Institute (NCI); Genentech, Inc.; Aventis Pharmaceuticals

Completed

Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Fred Hutchinson Cancer Center

Completed

Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Dutch Society of Physicians for Pulmonology and...

Completed

2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC) (NVALT10)

Carcinoma, Non-Small-Cell Lung

Netherlands
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer

Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx | Recurrent Squamous Cell Carcinoma of... and other conditions

United States
AbbVie (prior sponsor, Abbott)

Completed

Study of ABT-700 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

EGFR Gene Mutation

China
Gabi Chiorean, MD
Sanofi; OSI Pharmaceuticals

Terminated

Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas

Hepatocellular Carcinoma

United States
The Netherlands Cancer Institute
Dutch Society of Physicians for Pulmonology and Tuberculosis

Terminated

Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma

Carcinoma, Non-small Cell Lung

Netherlands
Fatebenefratelli and Ophthalmic Hospital
Niguarda Hospital; Mario Negri Institute for Pharmacological Research

Unknown

Tarceva Italian Lung Optimization tRial (TAILOR)

Non Small Cell Lung Cancer (NSCLC)

Italy
Fudan University

Unknown

Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC

Non Small Cell Lung Cancer

China
SCRI Development Innovations, LLC
Sanofi; Genentech, Inc.

Completed

Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC

Non-Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

Tongue Cancer | Stage III Squamous Cell Carcinoma of the Hypopharynx | Stage III Squamous Cell Carcinoma of the Larynx | Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage III Squamous Cell Carcinoma of the Nasopharynx | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage... and other conditions

United States
First Affiliated Hospital of Guangxi Medical University

Unknown

Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC

Non-small Cell Lung Cancer
Chinese PLA General Hospital

Unknown

A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations

Neoplasms, Lung | Carcinoma, Non-Small Cell Lung | Drug Therapy | Genes, EGFR

China
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

Australia, China, Korea, Republic of, Denmark, Germany, Greece, Russian Federation, Hungary, France, New Zealand, Spain, Austria, Slovakia, United Kingdom, Malaysia, Lithuania, South Africa, Slovenia, Italy, Canada, Belgium, Poland, Czech Republic and more
Ruijin Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001) (ALTER-G-001)

Gastrointestinal Tumors

China
Shandong Cancer Hospital and Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Qilu Hospital of Shandong University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer (ACDFNSNSCLC)

Non Small Cell Lung Cancer
The Affiliated Hospital of Qingdao University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer（ALTER-L034） (ACDFNSCLC)

Non Small Cell Lung Cancer
Yongchang Zhang

Recruiting

Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study (SAVE)

Non-Squamous Non Small Cell Lung Cancer

China
Yong Fang
Zhejiang Cancer Hospital; Zhejiang Provincial People's Hospital; Ningbo No. 1... and other collaborators

Unknown

Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC (ACWDVDFPTAN)

Non-small Cell Lung Cancer

China
China Medical University, China
General Hospital of Shenyang Military Region; Shengjing Hospital; The People's... and other collaborators

Unknown

A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC (ALTER-L024)

Non-small Cell Lung Cancer

China
ETOP IBCSG Partners Foundation
Biodesix, Inc.

Completed

Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. (EMPHASIS)

Carcinoma, Non-Small-Cell Lung

Ireland, Switzerland, Denmark, Spain, United Kingdom, Belgium, Hungary, Greece, Israel, Austria, Italy, Netherlands
Groupe Français de Pneumo-Cancérologie
Sanofi; Chugai Pharma USA

Completed

Elderly Independent Patients With Non Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

France
Guangdong Association of Clinical Trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

NSCLC

China
M.D. Anderson Cancer Center
Genentech, Inc.; Aventis Pharmaceuticals

Completed

Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Cancer

United States
Merck Sharp & Dohme LLC

Completed

A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)

Locally Advanced, Metastatic Solid Tumors
Shandong Cancer Hospital and Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients

Non Small Cell Lung Cancer

China
Wake Forest University Health Sciences
National Cancer Institute (NCI); OSI Pharmaceuticals

Completed

Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer | Large Cell Lung Cancer | Adenosquamous Cell Lung Cancer

United States
Tongji Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC (ALTER-L013)

NSCLC

China
Eli Lilly and Company

Terminated

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

Colorectal Cancer | Non-Small Cell Lung Cancer | Advanced Solid Tumor

United States, Australia
Finnish Lung Cancer Group
Roche Pharma AG

Completed

Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC

Non-small Cell Lung Cancer

Finland
Duke University
Genentech, Inc.

Completed

Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)

Glioblastoma | Gliosarcoma

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

United States
M.D. Anderson Cancer Center
Astellas Pharma Inc; The Kadoorie Charitable Foundations

Recruiting

Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection

Head and Neck Cancer

United States
Asan Medical Center
Korean Cancer Study Group; Boryung Pharmaceutical Co., Ltd

Recruiting

A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer (BRISK)

Advanced Solid Tumors | Metastatic Cancer | Solid Tumors

Korea, Republic of
Sichuan Cancer Hospital and Research Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC

Lung Cancer | Lung Cancer Metastatic

China
Azaya Therapeutics, Inc.

Completed

Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies

Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Solid Tumor | Non-Small Cell Lung

United States

Search clinical trials for: Docetaxel, Erlotinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations